Actavis’ Pulmicort Respules Generics Race Out The Door Before “Short Injunction”
Executive Summary
The company is barred from further distributing its budesonide inhalation suspension until April 12; the generic launched April 1 following a patent victory over AstraZeneca, but a New Jersey federal judge said a “limited temporary injunction” was warranted to give the innovator time to seek appellate relief.
You may also be interested in...
Actavis’ Launch Of Pulmicort Respules Generic Halted By Court
One day after declaring one Pulmicort patent invalid and another not infringed, a New Jersey federal judge granted AstraZeneca’s bid to temporarily block Actavis and other ANDA filers from launching and distributing their budesonide generics.
On Soriot’s List For AstraZeneca: Building A Decision-Making Culture
AstraZeneca investors will have to wait two more months to hear details of CEO Pascal Soriot’s plans for re-energizing the struggling big pharma. But the new chief did discuss several near-term objectives for the company and what he has pinpointed as being some of the operational problems, based on discussion with hundreds of employees, during a year-end financial call Jan. 31.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.